- Detect Alzheimer’s years before symptoms show up: All you need are a blood test and brain scan The Indian Express —
- Blood test could detect signs of Alzheimer’s ‘decades before symptoms’ – study The Argus —
- How a simple blood test could spot signs of Alzheimer’s ‘decades before symptoms’ The Independent —
- Judith Chalmers, presenter of TV series Wish You Were Here, dies aged 90 The Guardian —
- ITV Wish You Were Here? star Judith Chalmers dies aged 90 after health battle Coventry Live —
- First sign of Alzheimer's appears in midlife and is simple to spot Kent Live —
- Blood test could detect signs of Alzheimer’s ‘decades before symptoms’ – study The Independent —
- Blood test could detect signs of Alzheimer’s ‘decades before symptoms’ – study The Standard —
- ITV Wish You Were Here star Judith Chalmers dies aged 90 after Alzheimer's battle MyLondon —
- Judith Chalmers, Wish You Were Here...? host, dies at 90 RTE —
- First sign of Alzheimer's appears in midlife and is simple to spot Glasgow Live —
- Alzheimer's disease could be diagnosed years before symptoms become devastating - as researchers hail TWO new breakthroughs in blood tests and brain scans Daily Mail —
- Blood test suggests Alzheimer’s 'present in midlife' decades before symptoms start Mirror —
- Beloved Wish You Were Here presenter Judith Chalmers dies at 90 Belfast Live —
- TV star Judith Chalmers dies aged 90 after Alzheimer's battle as tributes pour in Yorkshire Live —
- Former Wish You Were Here…? presenter Judith Chalmers dies aged 90 The Standard —
- Iconic TV star Judith Chalmers dies aged 90 after Alzheimer's battle Nottinghamshire Live —
- Wish You Were Here presenter Judith Chalmers dies aged 90 after Alzheimer's battle Birmingham Live —
- Wish You Were Here host Judith Chalmers dies aged 90 after Alzheimer's battle Lancs Live —
- Judith Chalmers dead: Host of ITV's Wish You Were Here...? dies aged 90 after Alzheimer's battle The Standard —
Alzheimer's Disease Neuroimaging Initiative
Multisite study
Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.
Also known as...
ADNI, Alzheimer’s Disease Neuroimaging Initiative, and Alzheimer Disease Neuroimaging Initiative
Alzheimer's Blood Test Breakthrough